CD14 Blockade Modulates Macrophage-Mediated Immunological Injury in a Translational Model of Reperfused ST-Segment Elevation Myocardial Infarction

These preclinical trials provide the first evidence of cluster of differentiation 14 (CD14) blockade with a murine analogue of atibuclimab, a CD14-neutralizing antibody, preventing secondary immunological exacerbation of cardiac injury in a translational mouse model of reperfused ST-segment elevation myocardial infarction (STEMI), assessed using multiple clinical modalities. Multiomic studies suggest CD14 blockade downregulated macrophage-specific proinflammatory and tissue-wide remodeling processes without suppression of monocyte-macrophage infiltration or repair. These findings support a clinically practicable targeted immunomodulatory strategy of CD14 blockade initiated at reperfusion to prevent chronic immunological progression toward ischemic heart failure, and provide new insights into the pleiotropic roles of CD14 in inflammation and myocardial injury.

Authors

Institutions

Publication Details

Journal
JACC Basic to Translational Science
Published
2025-10-23
DOI
https://doi.org/10.1016/j.jacbts.2025.101393
Primary Topic
Cardiac Fibrosis and Remodeling
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

CD14 Blockade Modulates Macrophage-Mediated Immunological Injury in a Translational Model of Reperfused ST-Segment Elevation Myocardial Infarction

Junedh Amrute, Alexander R. Pinto, David M. Kaye, Kory J. Lavine et al.
JACC Basic to Translational Science
Cardiac Fibrosis and Remodeling
article

CD14 Blockade Modulates Macrophage-Mediated Immunological Injury in a Translational Model of Reperfused ST-Segment Elevation Myocardial Infarction

Junedh Amrute, Alexander R. Pinto, David M. Kaye, Kory J. Lavine, Angela Vais, Chad Johnson, Brian W. Ziegelaar, Haoyun Fang, Mark W. Appleby, Helen Kiriazis, Stéphanie Jansen, Ian C. Hsu, David W. Greening, Anita C. Thomas, Gabriella E. Farrugia, David Crowe, Jason Bloom, Malathi S.I. Dona, Crisdion Krstevski, Adam Parslow, Camilla Cohen, Garry Redlich, Antonio Abbate, Julie R. McMullen, Yow Keat Tham, D. Donner, Jonathan Noonan, Waled Shihata, Bing H. Wang, Guy Y. Krippner, David Wright, Natalia Carvajal, K. Grigolon, Andrew Brown, S. Loh
article en

Abstract

These preclinical trials provide the first evidence of cluster of differentiation 14 (CD14) blockade with a murine analogue of atibuclimab, a CD14-neutralizing antibody, preventing secondary immunological exacerbation of cardiac injury in a translational mouse model of reperfused ST-segment elevation myocardial infarction (STEMI), assessed using multiple clinical modalities. Multiomic studies suggest CD14 blockade downregulated macrophage-specific proinflammatory and tissue-wide remodeling processes without suppression of monocyte-macrophage infiltration or repair. These findings support a clinically practicable targeted immunomodulatory strategy of CD14 blockade initiated at reperfusion to prevent chronic immunological progression toward ischemic heart failure, and provide new insights into the pleiotropic roles of CD14 in inflammation and myocardial injury.

JACC Basic to Translational ScienceVol. 10(11)
Baker Heart and Diabetes Institute (AU), La Trobe University (AU), Washington University in St. Louis (US), Blaze Bioscience (United States) (US), Monash Health (AU), Alfred Health (AU), University of Virginia (US), Monash University (AU)
Openalex Percentile: Top 54%
Cardiac Fibrosis and Remodeling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.